Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 6340 Sequence Dr SAN DIEGO CA 92121-4356 |
Tel: | N/A |
Website: | https://www.dexcom.com |
IR: | See website |
Key People | ||
Kevin R. Sayer Chairman of the Board, President, Chief Executive Officer | Teri Lawver Executive Vice President - Chief Commercial Officer | Jereme M. Sylvain Chief Financial Officer, Executive Vice President |
Jacob Steven Leach Executive Vice President, Chief Operating Officer | Sadie M. Stern Chief Human Resource Officer, Executive Vice President | Girish Naganathan Executive Vice President, Chief Technology Officer |
Steven R. Pacelli Executive Vice President, Managing Director - Dexcom Ventures | Donald M. Abbey Executive Vice President, Global Business Services, IT Quality and Regulatory Affairs | Michael Brown Executive Vice President, Chief Legal Officer | Matthew Vincent Dolan Executive Vice President - Strategy, Corporate Development and Dexcom Labs |
Business Overview |
DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient's compatible mobile device. |
Financial Overview |
For the fiscal year ended 31 December 2023, DexCom Inc revenues increased 24% to $3.62B. Net income increased 59% to $541.5M. Revenues reflect United States segment increase of 23% to $2.63B, Outside of United states segment increase of 30% to $997M. Net income benefited from Income from equity investments increase from $200K to $1.9M (income), Interest on lease liabilities decrease of 3% to $3.2M (expense). |
Employees: | 9,600 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $52,399M as of Dec 31, 2023 |
Annual revenue (TTM): | $3,622M as of Dec 31, 2023 |
EBITDA (TTM): | $800.30M as of Dec 31, 2023 |
Net annual income (TTM): | $541.50M as of Dec 31, 2023 |
Free cash flow (TTM): | $511.90M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 385,515,421 as of Feb 1, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |